A significantly higher proportion of patients achieved an ACR20 at week 24 with secukinumab 300 mg ( 54 [ 54 % ] patients ; odds ratio versus placebo 681 , 95 % CI 342-1356 ; p < 00001 ) , 150 mg ( 51 [ 51 % ] patients ; 652 , 325-1308 ; p < 00001 ) , and 75 mg ( 29 [ 29 % ] patients ; 232 , 114-473 ; p = 00399 ) versus placebo ( 15 [ 15 % ] patients ) .